SAN FRANCISCO , Sept. 26, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate
- Oral presentation to include new data from ASPIRO out to 48-weeks of follow-up in the earliest treated patients in dose Cohort 1, and preliminary safety and efficacy data from the sentinel patient in dose Cohort 2 - Oral presentation to be held during a session on new therapeutic modalities
SAN FRANCISCO , Aug. 29, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate in
- Designation granted based on positive interim data from ASPIRO clinical trial - RMAT designation enables closer and more frequent multidisciplinary interaction with FDA and includes all of the benefits of breakthrough therapy designation - Plan to meet with FDA to gain alignment on AT132
SAN FRANCISCO , Aug. 9, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Natalie Holles ,
- Muscle biopsy data demonstrate highly efficient tissue transduction as indicated by vector copy number, robust myotubularin protein expression as assessed by western blot, and significant improvement in histology in first three treated patients at 24-week timepoint - Efficacy
- ASPIRO update to include 24-week clinical data and muscle biopsy results from the first three treated patients - Conference call and webcast scheduled for Tuesday, August 7, 2018 at 8:00am EST SAN FRANCISCO , July 31, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a
SAN FRANCISCO , June 5, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the European Medicines
SAN FRANCISCO , June 5, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the European Medicines
SAN FRANCISCO , May 29, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R.
